Last edition
News about "GLP-1 receptor agonist "
Vanda Pharmaceuticals Launches Thetis Study to Test NEREUS for GLP-1 Agonist-Induced Vomiting
Vanda Pharmaceuticals launches Thetis study, a multicenter clinical trial testing NEREUS (oral tradipitant) to prevent vomiting in patients starting high-dose GLP-1 receptor agonists, evaluating safety and efficacy.
GLP-1 Receptor Agonist | 09/04/2026 | By News Bureau
Lupin has signed an exclusive licence, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, strengthening its diabetes portfolio and accelerating its expansion into the obesity treatment segment.
GLP-1 Receptor Agonist | 30/12/2025 | By News Bureau | 134
Eli Lilly Reports Positive Phase 3 Topline Results for Oral GLP-1 Orforglipron in Type 2 Diabetes
Eli Lilly and Company has announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials evaluating orforglipron for the treatment of type 2 diabetes.
GLP-1 Receptor Agonist | 16/10/2025 | By Dineshwori | 322
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy